Farily good outcome, page-6

Well watching pxs deliver a cracking deal and divulging how milestone were to be met was simply the icing on the cake. 3 years of watching anp languish is simply beyond frustration is all I will say.

Pharmaxis will receive an upfront payment of €27.5 million (approximately A$39m) and, subject to the continuing
successful development and commercialisation of the PXS4728A program, the following payments:
 up to a total of €55 million in development milestone payments tied to the commencement of phase 2 and
3 clinical trials
 up to a total of €140 million in regulatory milestone payments upon filing of applications for marketing
approval and receipt of regulatory and pricing approvals for a PXS4728A program product in the major
pharmaceutical markets (i.e., USA, EU, and China or Japan) for the first indication
 additional milestone payments similar in total to those set forth above upon achievement of the same
development and regulatory milestone events by a PXS4728A program product for a second indication
Page 2 of 2
 earn‐out payments on annual net sales of PXS4728A program products at tiered percentages starting in the
high single digits
 commercialisation milestone payments upon achievement of specified levels of annual net sales of
PXS4728A program products
Boehringer will be responsible for all development, regulatory, manufacturing and commercialisation activities. Under
the agreement, Boehringer has also acquired other SSAO/VAP‐1 inhibitor molecules related to PXS4728A and associated
patents.
No doubt anp has a future but in keeping with past performance their ideas on how to promote themselves leaves a lot to be desired.